Follow the EMPULSE: In ‐hospital initiation of empagliflozin for heart failure across the spectrum of left ventricular ejection fraction
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - April 24, 2024 Category: Cardiology Authors: Tann Lien,
Kishan Srikanth,
Andrew P. Ambrosy Tags: Invited Editorial Source Type: research
Sodium-Glucose Co-transporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have proven benefits on clinical outcomes in patients with heart failure (HF).1-6 However, this class of medications increases the risk of mycotic genital infections (MGIs) and urinary tract infections (UTIs), particularly within the first 3-6 months after their initiation.7,8,9 In the EMPEROR-Preserved and EMPEROR-Reduced trials, MGIs and UTIs were among the 3 most common adverse events in the empagliflozin group,1,2 highlighting the clinical relevance of these infections. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 24, 2024 Category: Cardiology Authors: Angela Duvalyan, Ricardo M. La Hoz, Darren K McGuire, Mark H. Drazner Tags: Review Article Source Type: research
Investigating the impact of empagliflozin on the retina of diabetic mice
CONCLUSION: EMPA mitigates inflammation and preserves BRB structure and function, suggesting that it may prevent DR or serve as an effective early treatment for DR.PMID:38653578 | DOI:10.1177/11206721241247585 (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - April 23, 2024 Category: Opthalmology Authors: Juan Chen Shenghui Zhang Yao You Siqi Hu Jiake Tang Chen Chen Wen Wen Ting Tang Qingwen Yu Xuhan Tong Chunyi Wang Wenbin Zhao Xinyan Fu Xingwei Zhang Mingwei Wang Wenyan Gong Source Type: research
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA –KIDNEY
ConclusionsEmpagliflozin safely reduced the risk of “kidney disease progression or cardiovascular death” in patients with CKD, with consistent effects in participants from Japan. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - April 20, 2024 Category: Urology & Nephrology Source Type: research
Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review
CONCLUSION: Early evidence suggests that dapagliflozin and empagliflozin are well tolerated in children. A clinical pharmacology rationale currently exists only for adolescents with diabetes mellitus.PROSPERO REGISTRATION NUMBER: CRD42023438162.PMID:38635113 | DOI:10.1007/s40272-024-00623-z (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 18, 2024 Category: Pediatrics Authors: Sebastiano A G Lava Craig Laurence Alessandro Di Deo Nicole Sekarski Michael Burch Oscar Della Pasqua Source Type: research
Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases
Physiol Res. 2024 Apr 18. Online ahead of print.ABSTRACTA new class of antidiabetic drugs - gliflozins (inhibitors of sodium glucose cotransporter-2; SGLT-2i) stimulate glucose and sodium excretion, thereby contributing to improved glycemic control, weight loss and blood pressure reduction in diabetic patients. Large clinical trials in patients with type 2 diabetes treated with empagliflozin, canagliflozin or dapagliflozin have demonstrated their excellent efficacy in improving many cardiovascular outcomes, including the reduction of death from cardiovascular diseases, non-fatal myocardial infarction or stroke, and hospita...
Source: Physiological Research - April 18, 2024 Category: Physiology Authors: I Van ěčková J Zicha Source Type: research
Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review
CONCLUSION: Early evidence suggests that dapagliflozin and empagliflozin are well tolerated in children. A clinical pharmacology rationale currently exists only for adolescents with diabetes mellitus.PROSPERO REGISTRATION NUMBER: CRD42023438162.PMID:38635113 | DOI:10.1007/s40272-024-00623-z (Source: Paediatric Drugs)
Source: Paediatric Drugs - April 18, 2024 Category: Pediatrics Authors: Sebastiano A G Lava Craig Laurence Alessandro Di Deo Nicole Sekarski Michael Burch Oscar Della Pasqua Source Type: research
Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases
Physiol Res. 2024 Apr 18. Online ahead of print.ABSTRACTA new class of antidiabetic drugs - gliflozins (inhibitors of sodium glucose cotransporter-2; SGLT-2i) stimulate glucose and sodium excretion, thereby contributing to improved glycemic control, weight loss and blood pressure reduction in diabetic patients. Large clinical trials in patients with type 2 diabetes treated with empagliflozin, canagliflozin or dapagliflozin have demonstrated their excellent efficacy in improving many cardiovascular outcomes, including the reduction of death from cardiovascular diseases, non-fatal myocardial infarction or stroke, and hospita...
Source: Physiological Research - April 18, 2024 Category: Physiology Authors: I Van ěčková J Zicha Source Type: research
Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review
ConclusionEarly evidence suggests that dapagliflozin and empagliflozin are well tolerated in children. A clinical pharmacology rationale currently exists only for adolescents with diabetes mellitus.Prospero Registration NumberCRD42023438162. (Source: Pediatric Drugs)
Source: Pediatric Drugs - April 18, 2024 Category: Pediatrics Source Type: research
Kidney and Cardiovascular Effectiveness of Empagliflozin Compared to Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes
Placebo-controlled trials of sodium-glucose cotransporter-2 inhibitors (SGLT2i) demonstrate kidney and cardiovascular benefits for people with type 2 diabetes (T2D) and chronic kidney disease (CKD). We used real-world data to compare the kidney and cardiovascular effectiveness of empagliflozin to dipeptidyl peptidase-4 inhibitors (DPP4i), a commonly prescribed antiglycemic medication, in a diverse population with and without CKD. Using electronic health record data from 20 large US health systems, we leveraged propensity overlap weighting to compare outcomes for empagliflozin and DPP4i initiators with T2D between 2016 and ...
Source: The American Journal of Cardiology - April 17, 2024 Category: Cardiology Authors: Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, Karen Chiswell, Zachary Lampron, Christina Shay, Keith Marsolo, W. Schuyler Jones, Javed Butler, Raj C. Shah, Alanna M. Chamberlain, Daniel E. Ford, Howard S. Gordon, Wenke Hwang, Alexander Chang, Ajaykum Source Type: research
Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial
This study aims to assess the effect of evolocumab plus empagliflozin vs. empagliflozin alone on HDL subspecies isolated from individuals with type 2 diabetes mellitus (T2D). This post hoc prespecified analysis of the EXCEED-BHS3 trial compared the effects of a 16-week therapy with empagliflozin (E) alone or in combination with evolocumab (EE) on the lipid profile and cholesterol content in HDL subspecies in individuals with T2D divided equally into two groups of 55 patients. Both treatments modestly increased HDL-C. The cholesterol content in HDL subspecies 2a (7.3%), 3a (7.2%) and 3c (15%) increased from baseline in the ...
Source: Atherosclerosis - April 13, 2024 Category: Cardiology Authors: Isabella Bonilha Érica Ivana Lázaro Gomes Helison R P Carmo Ikaro Breder Joaquim Barreto Jessica Breder Daniel B Munhoz Luiz Sergio F Carvalho Thiago Quinaglia Sheila T Kimura-Medorima Camila Moreira Gossi Francesca Zimetti Wilson Nadruz Ilaria Zanotti Source Type: research
Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial
This study aims to assess the effect of evolocumab plus empagliflozin vs. empagliflozin alone on HDL subspecies isolated from individuals with type 2 diabetes mellitus (T2D). This post hoc prespecified analysis of the EXCEED-BHS3 trial compared the effects of a 16-week therapy with empagliflozin (E) alone or in combination with evolocumab (EE) on the lipid profile and cholesterol content in HDL subspecies in individuals with T2D divided equally into two groups of 55 patients. Both treatments modestly increased HDL-C. The cholesterol content in HDL subspecies 2a (7.3%), 3a (7.2%) and 3c (15%) increased from baseline in the ...
Source: Atherosclerosis - April 13, 2024 Category: Cardiology Authors: Isabella Bonilha Érica Ivana Lázaro Gomes Helison R P Carmo Ikaro Breder Joaquim Barreto Jessica Breder Daniel B Munhoz Luiz Sergio F Carvalho Thiago Quinaglia Sheila T Kimura-Medorima Camila Moreira Gossi Francesca Zimetti Wilson Nadruz Ilaria Zanotti Source Type: research
Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice
Am J Physiol Cell Physiol. 2024 Apr 1;326(4):C1272-C1290. doi: 10.1152/ajpcell.00446.2023. Epub 2024 Mar 4.ABSTRACTSodium-glucose cotransporter, type 2 inhibitors (SGLT2i) are emerging as the gold standard for treatment of type 2 diabetes (T2D) with renal protective benefits independent of glucose lowering. We took a high-level approach to evaluate the effects of the SGLT2i, empagliflozin (EMPA) on renal metabolism and function in a prediabetic model of metabolic syndrome. Male and female 12-wk-old TallyHo (TH) mice, and their closest genetic lean strain (Swiss-Webster, SW) were treated with a high-milk-fat diet (HMFD) plu...
Source: Am J Physiol Cell Ph... - April 11, 2024 Category: Cytology Authors: Blythe D Shepard Jennifer Chau Ryan Kurtz Avi Z Rosenberg Pinaki Sarder Samuel P Border Brandon Ginley Olga Rodriguez Chris Albanese Grace Knoer Aarenee Greene Aline M A De Souza Suman Ranjit Moshe Levi Carolyn M Ecelbarger Source Type: research
Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice
Am J Physiol Cell Physiol. 2024 Apr 1;326(4):C1272-C1290. doi: 10.1152/ajpcell.00446.2023. Epub 2024 Mar 4.ABSTRACTSodium-glucose cotransporter, type 2 inhibitors (SGLT2i) are emerging as the gold standard for treatment of type 2 diabetes (T2D) with renal protective benefits independent of glucose lowering. We took a high-level approach to evaluate the effects of the SGLT2i, empagliflozin (EMPA) on renal metabolism and function in a prediabetic model of metabolic syndrome. Male and female 12-wk-old TallyHo (TH) mice, and their closest genetic lean strain (Swiss-Webster, SW) were treated with a high-milk-fat diet (HMFD) plu...
Source: American Journal of Physiology. Cell Physiology - April 11, 2024 Category: Cytology Authors: Blythe D Shepard Jennifer Chau Ryan Kurtz Avi Z Rosenberg Pinaki Sarder Samuel P Border Brandon Ginley Olga Rodriguez Chris Albanese Grace Knoer Aarenee Greene Aline M A De Souza Suman Ranjit Moshe Levi Carolyn M Ecelbarger Source Type: research
Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice
Am J Physiol Cell Physiol. 2024 Apr 1;326(4):C1272-C1290. doi: 10.1152/ajpcell.00446.2023. Epub 2024 Mar 4.ABSTRACTSodium-glucose cotransporter, type 2 inhibitors (SGLT2i) are emerging as the gold standard for treatment of type 2 diabetes (T2D) with renal protective benefits independent of glucose lowering. We took a high-level approach to evaluate the effects of the SGLT2i, empagliflozin (EMPA) on renal metabolism and function in a prediabetic model of metabolic syndrome. Male and female 12-wk-old TallyHo (TH) mice, and their closest genetic lean strain (Swiss-Webster, SW) were treated with a high-milk-fat diet (HMFD) plu...
Source: Am J Physiol Cell Ph... - April 11, 2024 Category: Cytology Authors: Blythe D Shepard Jennifer Chau Ryan Kurtz Avi Z Rosenberg Pinaki Sarder Samuel P Border Brandon Ginley Olga Rodriguez Chris Albanese Grace Knoer Aarenee Greene Aline M A De Souza Suman Ranjit Moshe Levi Carolyn M Ecelbarger Source Type: research
